Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20460416 | 0.99 | MAPK14 (0.76) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL5118675 | 0.89 | MAPK14 (0.76) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL5123294 | 0.88 | MAPK14 (0.71) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL5417561 | 0.88 | MAPK14 (0.71) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL20460391 | 0.87 | MAPK14 (0.64) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL20460535 | 0.87 | MAPK14 (1.00) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL20448701 | 0.87 | MAPK14 (0.69) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL20460415 | 0.86 | MAPK14 (0.98) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL5631004 | 0.85 | MAPK14 (1.00) | MAPK14CYP2C9 | |
| SCHEMBL14409070 | 0.85 | MAPK14 (0.67) | MAPK14CYP2C9MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550073-B2 | Benzamide derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-02-04 | — | — | US | disclosed |
| EP-3357916-A1 | BENZAMIDE DERIVATIVE | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550073-B2 | Benzamide derivative | CYP3A5, ABCB1, CYP2D6 | MAPK14 3791/4885CYP2C9 36/4885NPC1 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.